<unk>  is used to treat essential thrombocytosis, especially when the current treatment of the patient is insufficient. Essential thrombocytosis patients who are suitable for<unk>  often meet one or more of the following factors: * age over 60 years * platelet count over 1000×109/L * a history of thrombosis According to a 2005 Medical Research Council randomized trial, the combination of hydroxyurea with aspirin is superior to the combination of<unk>  and aspirin for the initial management of essential thrombocytosis. The hydroxyurea arm had a lower likelihood of myelofibrosis, arterial thrombosis, and bleeding, but it had a slightly higher rate of venous thrombosis.<unk>  can be useful in times when hydroxyurea proves ineffective.
Anagrelide
Niclosamide
Epitiostanol
Pentoxifylline
Palladin
Gadoteric acid
Elinogrel
Sulfatide